SCHEMBL2037249

SCHEMBL2037249

FC(F)(F)COc1ccc(Br)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 3/20 0.44
APP P05067 1/20 0.42
GPR3 P46089 1/20 0.42
SCN5A Q14524 1/20 0.41
CYP17A1 P05093 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
PAX8 Q06710 1/20 0.40
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
DRD4 P21917 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL498377 0.88 ALDH1A1 (0.56) ALDH1A1MAPTKDM4EGPR3SCN5A
SCHEMBL16481262 0.83 ALDH1A1 (0.49) ALDH1A1MAPTKDM4EAPPSMN1; SMN2
SCHEMBL7762488 0.83 KDM4E (0.41) ALDH1A1MAPTKDM4EAPPDRD4
SCHEMBL16481270 0.83 ALDH1A1 (0.49) ALDH1A1MAPTKDM4EAPPRAB9A
SCHEMBL18380932 0.81 SCN5A (0.56) ALDH1A1MAPTKDM4EGPR3SCN5A
SCHEMBL14241918 0.79 ALDH1A1 (0.46) ALDH1A1MAPTKDM4EAPPSMN1; SMN2
SCHEMBL14227139 0.79 ALDH1A1 (0.46) ALDH1A1MAPTKDM4EAPPSMN1; SMN2
SCHEMBL7769868 0.79 HTT (0.47) ALDH1A1MAPTKDM4EAPPSMN1; SMN2
SCHEMBL4800915 0.79 MAPT (0.53) ALDH1A1MAPTAPPGPR3SCN5A
SCHEMBL122100 0.78 ALDH1A1 (0.44) ALDH1A1MAPTKDM4EGPR3SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110950743-B Difluoroethyleneoxy biphenyl diluent for high-birefringence liquid crystal and synthetic method thereof 陕西师范大学 2022-10-21 CN claimed
CN-110950743-A Difluoroethyleneoxy biphenyl diluent for high-birefringence liquid crystal and synthetic method thereof 陕西师范大学 2020-04-03 CN claimed
CN-110922988-A Large dielectric anisotropy difluoroethyleneoxy diphenylacetylene type diluent and synthetic method thereof 陕西师范大学 2020-03-27 CN claimed
US-12528802-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-01-20 US disclosed
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2025-11-25 US disclosed
US-20250353828-A1 SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY OREGON HEALTH & SCIENCE UNIVERSITY (US) 2025-11-20 US disclosed
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use AMGEN INC. (US) 2025-11-18 US disclosed
US-12448396-B2 Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors AMGEN INC. (US) 2025-10-21 US disclosed
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND SHOUYAO HOLDINGS BEIJING CO LTD (CN) 2025-07-10 US disclosed
EP-4536639-A1 SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY Oregon Health & Science University (US) 2025-04-16 EP disclosed
CN-119735904-A PVDF profile and preparation process thereof 氟特高新材料(无锡)有限公司 2025-04-01 CN disclosed
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors PHARMACIA CORPORATION 2004-07-22 US disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US disclosed
WO-2004018448-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2004-03-04 WO disclosed
WO-2002066413-A1 FLECAINIDE SYNTHESIS NARCHEM CORPORATION (US) 2002-08-29 WO disclosed
EP-0727428-B1 Novel silacyclohexane compounds, preparation thereof, liquid crystal compositions comprising the same, and liquid crystal devices comprising the compositions SHINETSU CHEMICAL CO (JP) 2001-06-06 EP disclosed
US-5665271-A Silacyclohexane compounds, preparation thereof, liquid crystal compositions comprising the same, and liquid crystal devices comprising the compositions SHIN-ETSU CHEMICAL CO., LTD. (JP) 1997-09-09 US disclosed
EP-0727428-A1 Novel silacyclohexane compounds, preparation thereof, liquid crystal compositions comprising the same, and liquid crystal devices comprising the compositions SHIN-ETSU CHEMICAL CO., LTD. (JP) 1996-08-21 EP disclosed
US-4864032-A Process for the preparation of indazoles ORTHO PHARMACEUTICAL CORPORATION 1989-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353828-A1 SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY EPX, TFEB, EPHX1 ALDH1A1 2498/4885MAPT 3447/4885KDM4E 2282/4885
US-12448396-B2 Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors SCD5, SCD, FADS2 ALDH1A1 398/4885MAPT 4549/4885KDM4E 1019/4885
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DGKK, DGKG, DGKA ALDH1A1 3915/4885MAPT 4812/4885KDM4E 1315/4885
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors MMP3, MMP13, MMP10 ALDH1A1 1789/4885MAPT 3438/4885KDM4E 1844/4885
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND MAPT, MNAT1, MAT2A ALDH1A1 996/4885MAPT 1/4885KDM4E 3698/4885
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them MMP11, MMP13, CBR1 ALDH1A1 563/4885MAPT 3516/4885KDM4E 2797/4885
US-12528802-B2 Heterocyclic compound GBA2, GBA1, GALC ALDH1A1 2563/4885MAPT 2291/4885KDM4E 2781/4885
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use SCD5, SCD, FADS2 ALDH1A1 326/4885MAPT 4509/4885KDM4E 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.